The reviewer language, root causes, and response patterns behind the cybersecurity deficiencies that hold up 510(k), De Novo, PMA, and IDE submissions.
When the FDA reviews a 510(k), De Novo, or PMA submission for a cyber device, the cybersecurity package is screened against the requirements in Section 524B of the FD&C Act and the 2026 premarket cybersecurity guidance. If something is missing, inconsistent, or unverifiable, the reviewer issues an Additional Information (AI) request - commonly called a deficiency letter - listing each cybersecurity finding the manufacturer must close before the submission can advance.
The letter pauses the FDA review clock and starts a separate 180-day response window. If the manufacturer does not provide a complete response within that window, the submission is closed and must be refiled. Most cybersecurity deficiency letters contain between three and twelve findings, and the same handful of issues account for the overwhelming majority of them.
This hub decodes the ten most common FDA cybersecurity deficiency patterns. For each one we cover the reviewer language you are likely to see, why the issue keeps recurring, and a concrete checklist for closing it.
Each topic links to a dedicated page with the reviewer language, root causes, and remediation checklist.
Reviewers say your STRIDE/attack-tree analysis misses interfaces, trust boundaries, or post-market threat surfaces.
Read the breakdownYour SBOM is missing required minimum elements, transitive dependencies, or is delivered in an unsupported format.
Read the breakdownYour submission is missing one or more of the architecture views FDA 2026 expects (global system, multi-patient, updateability).
Read the breakdownReviewers find your penetration test scope too narrow, methodology unclear, or testers insufficiently independent.
Read the breakdownReviewers cannot find a cybersecurity risk assessment distinct from the ISO 14971 safety risk file, or the integration is unclear.
Read the breakdownYour VM plan lacks defined triage timelines, a coordinated vulnerability disclosure path, or a documented patch-deploy mechanism.
Read the breakdownReviewers cannot find the CVE-to-component or CWE-to-weakness mapping that lets them verify your vulnerability posture.
Read the breakdownReviewers want test evidence that secure boot, signed updates, and root-of-trust controls function as claimed.
Read the breakdownReviewers cannot find evidence that your QMS implements a Secure Product Development Framework integrated with design controls.
Read the breakdownYour post-market plan lacks monitoring, patching commitments, customer communications, or end-of-support handling.
Read the breakdownOur team handles deficiency response as a focused engagement. We translate every finding back to the underlying artifact - threat model, SBOM, architecture views, risk assessment, pen test report, post-market plan - rebuild it to FDA 2026 expectations, and produce a reviewer-ready response narrative that traces each finding to the specific evidence that closes it.
In a deficiency response cycle now?
Bring us the letter. We will tell you, within one call, which of the patterns above you are facing and what a clean response looks like.
Book a strategy sessionPaste the FDA cybersecurity AI request, get a structured categorization and evidence checklist.
We have closed cybersecurity deficiencies on hundreds of FDA submissions. Bring us the letter and we will map a clean response.
